comprehensive -WSS

comprehensive

author：knowledge 2025-09-30 00:08:51 - browse：794

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： FDA panel signals lack of confidence in Amgen cancer drug data

WSS

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Analysis of telehealth claims data suggest service duplication

MoonLake credibility takes another hit with mid

FDA authorizes Novavax’s updated Covid

Why age limits for politicians are a terrible idea

What to expect at HLTH 2023, the health care industry conference

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

The high cost of giving birth even with insurance

10 million people disenrolled from Medicaid over past six months

Peter Hotez and the public health issue of online harassment

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

In age of alternative facts, a scholarly course on calling out crap

Victims of gun violence feel impacts long after bullet wound

Activists slam private health insurers over coverage restrictions

Just how powerful is the placebo effect?

Wildfire smoke exposes gaps in outdoor worker protections

Medicare will require more price transparency from hospitals

entertainment

Histogen: Failed biotech offers rare public look inside

The Sacklers, horror, and ‘The Fall of the House of Usher’

Removing probiotics from the NICU could threaten preemies' health

More doctors should go into startup world

Analysis of telehealth claims data suggest service duplication

The Sacklers, horror, and ‘The Fall of the House of Usher’

hotspot

explore

knowledge

hotspot